Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Renal indexChapter sections
Purpose and principlesIndications, selection and cautionsMethod and interpretationClinical next stepsProcedure and medicine safetyRisks, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Interpreting creatinine, eGFR and urea

Renal · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

A rapidly rising creatinine with oliguria, severe hyperkalaemia, metabolic acidosis, pulmonary oedema, uraemic encephalopathy or pericarditis needs urgent clinical assessment and nephrology escalation. Dialysis decisions are made on complications and trajectory, never an isolated urea or eGFR threshold.

Purpose and principles

Interpret renal biochemistry through time, understand creatinine and eGFR limitations, distinguish acute from chronic dysfunction and avoid unsafe dosing or referral decisions based on one number.

Creatinine and urea are concentration markers, not direct measurements of kidney damage. Creatinine-based equations estimate filtration in stable populations and perform best when muscle generation and distribution are typical. They do not show nephron inflammation, obstruction, albumin leakage or tubular function; urine testing and imaging remain complementary.

The interpretation sequence is baseline, rate of change, urine output, complications and context. An eGFR of 25 may be a stable chronic state with a mature plan, while a fall from 95 to 55 in 48 hours is acute and potentially dangerous despite the higher absolute number. Percentage and timing matter.

For chronic prognosis, combine eGFR and ACR, calculate Kidney Failure Risk Equation where NICE indicates and assess progression. For medicine safety, use the renal measure specified in the BNF or SmPC rather than assuming laboratory eGFR is interchangeable with creatinine clearance.

Key points

  • Serum creatinine is produced from muscle metabolism and influenced by muscle mass, diet, supplements, hydration, tubular secretion and some medicines; a 'normal' value can conceal major impairment in a frail person.
  • Creatinine rises only after filtration has fallen and distribution has evolved. During acute kidney injury it lags the insult, so creatinine-based eGFR is mathematically precise but physiologically invalid at non-steady state.
  • NICE detects AKI using a creatinine rise of at least 26 micromol/L within 48 hours, a rise of at least 50% within seven days, or defined oliguria, applied against a credible baseline.
  • Chronic kidney disease requires abnormal structure or function present for more than three months. One eGFR below 60 cannot distinguish transient AKI, biological variation or established CKD.
  • Classify chronic disease with both GFR category G1 to G5 and albuminuria category A1 to A3 because ACR materially changes renal and cardiovascular risk at the same eGFR.
  • eGFR is indexed to 1.73 square metres. Drug dosing may require Cockcroft-Gault creatinine clearance or a de-indexed estimate, particularly for direct oral anticoagulants and extremes of body size.
  • Do not use routine eGFR equations in pregnancy; follow serum creatinine and the renal-obstetric pathway. Interpret cautiously in amputees, severe muscle wasting, bodybuilders, oedema and rapidly changing function.

Indications, selection and cautions

Acute biochemical patternRed flag

A qualifying creatinine rise over hours or days, falling urine output and a new precipitant supports AKI. Hyperkalaemia, acidosis, pulmonary oedema and uraemic features determine immediate severity.

Chronic biochemical pattern

Similar abnormal results separated by at least three months, longstanding albuminuria, anaemia, mineral-bone abnormalities or small echogenic kidneys support CKD, but none prevents superimposed AKI.

Low-muscle-mass trap

Frailty, paralysis, amputation, cirrhosis or cachexia reduces creatinine generation, so apparently reassuring creatinine and eGFR may overestimate true filtration and drug clearance.

High-creatinine-generation trap

Large muscle mass, recent cooked meat, creatine supplements or intense exercise can raise creatinine without equivalent structural injury. Repeat under standard conditions while checking urinalysis and clinical context.

Disproportionate urea

Marked urea elevation with lesser creatinine change may occur in dehydration, catabolism, steroid exposure or gastrointestinal bleeding. It can contribute to uraemic symptoms but does not localise renal pathology alone.

Method and interpretation

  1. 01
    Previous creatinine and eGFR resultsFirst step
    Why
    Define a credible baseline, chronicity and speed of change.
    Interpretation and limitations
    Use the most recent stable value before illness rather than an already deteriorating admission sample. Plot results and note intervening medication, weight, pregnancy or dialysis changes.
  2. 02
    Repeat U&E and venous blood gas
    Why
    Confirm trajectory and identify potassium or acid-base complications.
    Interpretation and limitations
    Choose urgency from the clinical scenario; severe potassium or bicarbonate abnormalities need immediate action. Laboratory haemolysis can falsely raise potassium but should be repeated rapidly without delaying treatment when ECG changes exist.
  3. 03
    Measured urine output
    Why
    Detect AKI earlier and assess response independently from lagging creatinine.
    Interpretation and limitations
    Use actual weight and time period where possible, checking catheter patency and losses. Diuretics change volume but do not prove filtration recovery.
  4. 04
    Urine ACR and reagent-strip urinalysis
    Why
    Add kidney-damage and sediment information to filtration estimates.
    Interpretation and limitations
    Persistent ACR at least 3 mg/mmol establishes albuminuria and modifies CKD risk. Blood plus protein may require nephrology assessment even with a preserved eGFR.

Clinical next steps

01New high creatinineDetermine acute, chronic or bothFirst stepFirst recognised creatinine elevation or eGFR below the reference range.+
  1. 1Retrieve baseline values, measure urine output, assess illness, volume, obstruction and medicines, and repeat urgently when AKI criteria or serious complications are possible.
  2. 2Perform urinalysis, ACR and appropriate imaging; classify an acute rise by NICE criteria rather than accepting the automated eGFR stage.
  3. 3If stable but chronicity is uncertain, repeat within the NICE timeframe to exclude rapid deterioration and then confirm persistence beyond three months before labelling CKD.
02Established CKDClassify risk rather than eGFR aloneKidney abnormality documented for at least three months.+
  1. 1Assign G category and ACR category, record cause where known and calculate progression from serial values rather than two closely spaced noisy measurements.

Procedure and medicine safety

Illustrates a high-risk class for which laboratory eGFR should not replace the specified creatinine-clearance method.

Direct oral anticoagulants

Select agent and dose from the licensed indication using Cockcroft-Gault creatinine clearance, age, weight and interacting medicines, with pharmacy support when uncertain.

Overestimated function increases bleeding risk. Recalculate during illness, weight change and renal decline; dialysis and very low clearance have drug- and indication-specific restrictions.

Glucose-lowering therapy whose accumulation and lactic-acidosis risk rise in severe impairment or acute hypoxia, sepsis and dehydration.

Metformin

Use current BNF and SmPC eGFR thresholds, dose review and monitoring; do not infer safety from one creatinine value during acute illness.

Manufacturer advice avoids use below the specified severe eGFR threshold. Temporarily review during AKI or major physiological stress and create an explicit restart plan after recovery.

Risks, monitoring and follow-up

  • In suspected AKI, repeat creatinine, potassium and bicarbonate at a frequency driven by severity and treatment, while recording hourly or cumulative urine output where indicated.
  • After AKI, arrange creatinine and albuminuria follow-up based on recovery and residual risk; a discharge value near baseline does not eliminate later CKD risk.
  • In CKD, monitor both eGFR and ACR according to G/A category, progression and medicines, avoiding falsely precise conclusions from changes within expected biological variation.
  • After starting or increasing an ACE inhibitor or ARB, follow creatinine and potassium at the NICE interval and interpret percentage change before discontinuing kidney-protective therapy.
  • For renally cleared narrow-index medicines, pair renal estimates with drug levels or clinical toxicity monitoring when applicable and recalculate after meaningful weight or renal changes.

Special situations

eGFR is a steady-state equation

When creatinine is rising, the equation assumes a stable concentration that does not exist. Reported eGFR can therefore underestimate the severity and timing of acute loss.

The lower absolute value is not always worse

Risk from a chronic eGFR of 25 differs from an acute fall to 55. Trajectory, potassium, acid-base state, urine output and symptoms define urgency.

Indexing changes drug questions

Laboratory eGFR is normalised to body surface area for CKD classification. Some drug decisions require absolute clearance or Cockcroft-Gault, especially at body-size extremes.

Urea is a systemic metabolite

Protein load, bleeding, steroids and catabolism can alter urea independently of filtration. It is useful context but cannot be treated as a pure renal-function gauge.

Dialysis changes the number, not history

A post-dialysis creatinine or urea is mechanically reduced and cannot be compared with an untreated baseline as evidence that native filtration recovered.

Common pitfalls

  1. 01

    Using automated eGFR to stage a patient whose creatinine is changing rapidly.

  2. 02

    Diagnosing CKD from one low eGFR without demonstrating three-month persistence or structural damage.

  3. 03

    Reassuring a frail or amputee patient because serum creatinine lies within the population range.

  4. 04

    Dosing a direct oral anticoagulant from eGFR when the licence requires Cockcroft-Gault creatinine clearance.

  5. 05

    Starting dialysis from a urea threshold without assessing complications, symptoms and trajectory.

  6. 06

    Calling a diluted creatinine fall renal recovery after a large positive fluid balance.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
RenalOriginal SBA

eGFR during acute change

A patient's creatinine rises from 80 to 165 micromol/L over forty-eight hours, while the laboratory reports eGFR 34 mL/min/1.73 m². How should the eGFR be used?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Renal topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG148 acute kidney injury recommendationsCreatinine and urine-output AKI detection criteria.
  • NICE NG203 chronic kidney disease recommendationsChronicity, G/A classification, progression and risk assessment.
  • UKKA measurement of kidney functionUK interpretation of eGFR, creatinine and albuminuria.
  • NHS SPS calculating kidney functionCreatinine-clearance methods and medicine-dosing limitations.
  • BNF prescribing in renal impairmentNational renal-dose and estimation principles.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
  • Urea rises with reduced filtration but also dehydration, high protein intake, catabolism, corticosteroids and gastrointestinal bleeding; low urea occurs with low protein intake or severe liver dysfunction.
  • A disproportionate urea rise can support reduced renal perfusion or upper gastrointestinal bleeding but no fixed urea-to-creatinine ratio diagnoses the cause reliably in an individual patient.
  • Trends need context: a dilutional creatinine fall after large fluid balance does not necessarily mean renal recovery, and dialysis can lower values without restoring native function.
  • 05
    Creatinine clearance calculation for medicines
    Why
    Use the renal function estimate required by a drug's licensing and prescribing guidance.
    Interpretation and limitations
    Cockcroft-Gault uses age, sex, weight and creatinine, but weight selection is problematic at extremes. Confirm with pharmacy for narrow-therapeutic-index drugs, DOACs and dialysis.
  • 06
    Cystatin C or measured GFR in selected cases
    Why
    Refine filtration when creatinine generation is unusually unreliable and the result would change care.
    Interpretation and limitations
    Cystatin C has non-GFR influences including inflammation and steroids; radioisotope measured GFR is specialist testing used for specific dosing, donation or pre-treatment questions.
  • 2Use NICE monitoring frequency and KFRE in the specified G3a to G5 population, integrating age, comorbidity, albuminuria and patient priorities.
  • 3Treat cardiovascular and kidney risk, review medicines and refer for accelerated decline, high albuminuria, renal haematuria, resistant hypertension, diagnostic uncertainty or kidney-failure risk.
    • 03Prescription decisionMatch renal estimate to the medicineStarting, stopping or adjusting a renally cleared or nephrotoxic medicine.+
    1. 1Read the current BNF and SmPC to identify whether dosing is based on eGFR, Cockcroft-Gault creatinine clearance, dialysis modality or drug concentrations.
    2. 2Check whether function is stable; in AKI, use trajectory and specialist pharmacy because neither eGFR nor Cockcroft-Gault describes rapidly changing clearance accurately.
    3. 3Document the calculation, body weight used, dose, monitoring and trigger for reassessment after recovery, dehydration, dialysis change or interacting treatment.